Lifecare ASA: Mandatory notification of trade

The Company has been informed that Hannibal Invest AS, a company closely associated with Hans Hekland, board member and primary insider of Lifecare ASA, has exercised 705,196 warrants in Warrants Series 2 for the subscription of 705,196 new shares in the Company at a price of NOK 0.24899 per share. Following this transaction, Hannibal Invest AS holds 1,131,949 shares and no warrants in Warrant Series 2 in the Company. Subject to timely payment of the aggregate subscription amount for the new shares to be issued as a result of the exercise of Warrants Series 2 on the Payment Date, the Company expects that the share capital increase pertaining to the issuance of the new shares will be registered with the Norwegian Register of Business Enterprises on or about 25 June 2026 and that shares will be delivered to the VPS accounts of the subscribers to whom they are allocated on or about 26 June 2026. About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets. Contacts For further information, please contact: Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40 Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64 This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-06-11 08:10 CEST.